Related Experiment Videos
Targeting Lipid Metabolic Reprogramming to Overcome Immunotherapy Resistance: Systemic Nutritional Modulation and
Qi Li1,2, Jingyi Yang1,2, Daozhen Chen1,2,3
1Affiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, People's Republic of China.
International Journal of Nanomedicine
|July 20, 2026
Summary
Overcoming resistance to immune checkpoint inhibitors (ICIs) requires addressing the tumor microenvironment's lipid metabolism. Combining dietary Omega-3 fatty acids with nanotherapeutics offers a novel strategy to enhance anti-tumor immunity.
Area of Science:
- Oncology
- Immunology
- Metabolic Research
Background:
- Immune checkpoint inhibitors (ICIs) show clinical success but face resistance.
- Tumor microenvironment (TME) lipid metabolism, especially prostaglandin E2 (PGE2), drives resistance by suppressing CD8+ T cells and promoting immunosuppressive macrophages.
- Dietary Omega-6 fatty acids exacerbate PGE2 production, hindering nanotherapeutic efficacy.
Purpose of the Study:
- To propose a dual-compartment therapeutic framework combining systemic dietary modulation with precision nanotherapy to overcome ICI resistance.
- To integrate biological mechanisms with pharmaceutical design, considering translational barriers and formulation strategies for lipid reprogramming.
- To evaluate nanocarrier formulations for synergistic potential with nutritional interventions.
Main Methods:
- Reviewing literature on lipid metabolism in the TME and its impact on anti-tumor immunity.
- Analyzing the role of dietary fatty acids (Omega-6 and Omega-3) in modulating PGE2 biosynthesis.
- Evaluating advanced nanocarrier formulations (stimuli-responsive, lipid-targeted) for targeted delivery and therapeutic effect.
- Proposing a combinatorial strategy integrating dietary interventions with nanotherapeutics.
Main Results:
- High dietary Omega-6 intake creates a metabolic sink that limits the effectiveness of localized nanotherapies.
- Systemic Omega-3 dietary preconditioning can counteract Omega-6-driven PGE2 biosynthesis.
- Targeted nanotherapeutics, particularly lipid-targeted and stimuli-responsive carriers, show promise in combination with nutritional strategies.
- A dual-compartment approach is proposed to synergistically enhance anti-tumor immune responses.
Conclusions:
- Combining systemic Omega-3 dietary interventions with localized nanotherapeutics presents a biologically rational strategy to overcome lipid-driven immune evasion and ICI resistance.
- Addressing the host's nutritional baseline is critical for the in vivo efficacy of nanotherapeutics targeting the TME.
- Further rigorous translation of these combinatorial regimens is essential for improving patient outcomes and advancing clinical applications.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...